Compare EBAY & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBAY | ONC |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.4B | 34.8B |
| IPO Year | 1998 | N/A |
| Metric | EBAY | ONC |
|---|---|---|
| Price | $82.79 | $309.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 12 |
| Target Price | $94.12 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 3.8M | 284.8K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ 16.01 | N/A |
| EPS | ★ 4.60 | 0.58 |
| Revenue | ★ $10,714,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | $9.21 | $895.40 |
| Revenue Next Year | $4.65 | $22.04 |
| P/E Ratio | ★ $18.82 | $545.67 |
| Revenue Growth | 4.36 | ★ 50.43 |
| 52 Week Low | $58.71 | $170.99 |
| 52 Week High | $101.15 | $385.22 |
| Indicator | EBAY | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 37.64 |
| Support Level | $82.26 | $315.50 |
| Resistance Level | $85.66 | $326.77 |
| Average True Range (ATR) | 1.90 | 9.85 |
| MACD | 0.47 | -3.32 |
| Stochastic Oscillator | 44.59 | 20.98 |
EBay operates one of the largest e-commerce marketplaces in the world, with $75 billion in 2024 gross merchandise volume, rendering the firm a top 10 global e-commerce company. It generates sales from listing fees, advertising, revenue-sharing arrangements with service providers, and managed payments, with its platform connecting more than 130 million buyers and roughly 20 million sellers across almost 190 global markets at the end of 2024. EBay generates just north of 50% of its GMV in international markets, with a large presence in the UK, Germany, and Australia.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.